Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness
Open Access
- 6 October 2020
- journal article
- research article
- Published by Elsevier BV in International Journal of Infectious Diseases
- Vol. 101, 290-297
- https://doi.org/10.1016/j.ijid.2020.09.1486
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19New England Journal of Medicine, 2020
- Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, ItalyJama-Journal Of The American Medical Association, 2020
- Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort studyEuropean Respiratory Journal, 2020
- Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case reportAnnals Of Oncology, 2020
- Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortalityInternational Journal of Antimicrobial Agents, 2020
- Covid-19: what treatments are being investigated?Published by BMJ ,2020
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposalThe Journal of Heart and Lung Transplantation, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Comparison of the Sp o 2 /F io 2 Ratio and the Pa o 2 /F io 2 Ratio in Patients With Acute Lung Injury or ARDSSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2007